For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Araxes Pharma LLC

Calculating rank

USPTO Granted Patents = 46

% Expired Patents = 8.7

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 894

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Liansheng Li (46 out of 117 patents)

Pingda Ren (46 out of 140 patents)

Yi Liu (45 out of 153 patents)

4. Jun Feng (42 out of 85 patents)

5. Yuan Liu (29 out of 29 patents)

6. Tao Wu (25 out of 89 patents)

7. Yun Long (24 out of 35 patents)

8. Yi Wang (6 out of 41 patents)

9. Matthew Patricelli (2 out of 9 patents)

10. Neelakandha S Mani (1 out of 48 patents)

11. Matthew Robert Janes (1 out of 1 patent)

12. Xiaohu Deng (1 out of 22 patents)

13. Jimmy T Liang (1 out of 11 patents)

14. Zachary S Sales (1 out of 7 patents)

15. Ulf Peters (1 out of 1 patent)

Core Competencies:

KRAS G12C

Covalent Inhibitors

Quinazoline Compounds

Cancer Treatment

Mutant Proteins

Heterocyclic Compounds

Combination Therapies

Inhibition Methods

Fused Bicyclic Compounds

Substituted Quinazolines

Piperazines

Cereblon Binding

46 patents: Sort by Forward Citations

1. RE50527 - Covalent inhibitors of KRAS G12C (2025-08-12),

2. RE50490 - Substituted quinazoline compounds and methods of use thereof (2025-07-15),

3. 12234244 - Substituted piperazines as inhibitors of KRAS G12C (2025-02-25),

4. 12134620 - Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer (2024-11-05),

5. 11878985 - Substituted quinazolines as inhibitors of KRAS G12C (2024-01-23),

6. 11639346 - Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS (2023-05-02),

7. 11377441 - Covalent inhibitors of KRAS (2022-07-05),

8. 11358959 - Benzothiophene and benzothiazole compounds and methods of use thereof (2022-06-14),

9. 11279689 - 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer (2022-03-22),

10. 11274093 - Fused bicyclic benzoheteroaromatic compounds and methods of use thereof (2022-03-15),

11. 11136308 - Substituted quinazoline and quinazolinone compounds and methods of use thereof (2021-10-05),

12. 11059819 - Fused hetero-hetero bicyclic compounds and methods of use thereof (2021-07-13),

13. 11021470 - 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof (2021-06-01),

14. 10975071 - Inhibitors of KRAS G12C mutant proteins (2021-04-13),

15. 10927125 - Substituted cinnolines as inhibitors of KRAS G12C (2021-02-23),

Company Overview

Araxes Pharma LLC, based in San Diego, CA, specializes in the development of innovative cancer therapies. The company focuses on covalent inhibitors targeting KRAS G12C, utilizing advanced chemical compounds such as quinazolines and benzothiophenes. Their research emphasizes combination therapies and the design of fused bicyclic compounds to enhance treatment efficacy. By leveraging cutting-edge technology in oncology, Araxes Pharma aims to address unmet medical needs in cancer treatment and improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

46 Patents

#133 in San Diego, CA

#1,798 in California

#7,614 in US

#15,133 in the World

San Diego, CA, United States of America

Araxes Pharma LLC

Forward Citations = 894

17 inventors:

Liansheng Li (46 out of 117 patents)

Pingda Ren (46 out of 140 patents)

Yi Liu (45 out of 153 patents)

4. Jun Feng (42 out of 85 patents)

5. Yuan Liu (29 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Araxes Pharma LLC. Retrieved from https://idiyas.com/company/araxes-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…